Design and characterization of an ocular topical liposomal preparation to replenish the lipids of the tear film

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 12, 2014, Pages 7839-7847

  Vicario de la Torre, Marta ^a,b   Benítez del Castillo, José Manuel ^b   Vico, Eva ^b   Guzmán, Manuel ^c   de las Heras, Beatriz ^a   Herrero Vanrell, Rocío ^a,b   Molina Martínez, Irene T ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Dry eye; Liposomes; Nanotechnology

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; PHOSPHATIDYLCHOLINE; ANTIOXIDANT; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; DRUG FORMULATION; DRY EYE; FLOW KINETICS; HUMAN; HUMAN CELL; HYDRATION; LIPOSOMAL DELIVERY; MALE; MOUSE; NONHUMAN; OSMOLARITY; PH; PRIORITY JOURNAL; SHEAR RATE; SURFACE TENSION; TEAR FILM; ULTRASOUND; VISCOSITY; ANIMAL; CELL CULTURE; CONJUNCTIVA; CORNEA; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; DRY EYE SYNDROMES; MACROPHAGE; RABBIT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ALPHA-TOCOPHEROL; ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; CHOLESTEROL; CONJUNCTIVA; CORNEA; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; HUMANS; LIPOSOMES; MACROPHAGES; MICE; PHOSPHATIDYLCHOLINES; RABBITS; VISCOSITY;

EID: 84922482166     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14700     Document Type: Article

References (71)

1. Paulsen F. Functional anatomy and immunological interactions of ocular surface and adnexa. Dev Ophthalmol. 2008;41:21–35
2. Gipson IK. The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2007;48:4391–4398
3. Spurr-Michaud S, Argüeso P, Gipson IK. Assay of mucins in human tear fluid. Exp Eye Res. 2007;84:939–950
4. Green-Church KB, Butovich I, Willcox M, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on tear film lipids and lipidprotein interactions in health and disease. Invest Ophthalmol Vis Sci. 2011;52:1979–1993
5. Butovich IA. The Meibomian puzzle: combining pieces together. Prog Retin Eye Res. 2009;28:483–498
6. Rantamaki AH, Seppanen-Laakso T, Oresic M, Jauhiainen M, Holopainen JM. Human tear fluid lipidome: from composition to function. PLoS One. 2011;6:e19553
7. Saville JT, Zhao Z, Willcox MD, Ariyavidana MA, Blanksby SJ, Mitchell TW. Identification of phospholipids in human meibum by nano-electrospray ionisation tandem mass spectrometry. Exp Eye Res. 2010;92:238–240
8. Ham BM, Jacob JT, Keese MM, Cole RB. Identification, quantification and comparison of major non-polar lipids in normal and dry eye tear lipidomes by electrospray tandem mass spectrometry. J Mass Spectrom. 2004;39:1321–1336
9. McCulley JP, Shine W. A compositional based model for the tear film lipid layer. Trans Am Ophthalmol Soc. 1997;95:79–93
10. Rosenfeld L, Cerretani C, Leiske DL, Toney MF, Radke CJ, Fuller GG. Structural and rheological properties of meibomian lipid. Invest Ophthalmol Vis Sci. 2013;54:2720–2732
11. Nagyová B, Tiffany, JM. Components responsible for the surface tension of human tears. Curr Eye Res. 1999;19:4–11
12. McCulley J, Shine W. The lipid layer: the outer surface of the ocular surface tear film. Biosci Rep. 2001;21:407–418
13. McCulley JP, Shine WE. Meibomian gland and tear film lipids: structure, function and control. Adv Exp Med Biol. 2002;506: 373–378
14. Rosenfeld L, Fuller GG. Consequences of interfacial viscoelasticity on thin film stability. Langmuir. 2012;28:14238–14244
15. Schuett BS, Millar TJ. Lipid component contributions to the surface activity of meibomian lipids. Invest Ophthalmol Vis Sci. 2012;53:7208–7219
16. Millar TJ, King-Smith PE. Analysis of comparison of human meibomian lipid films and mixtures with cholesteryl esters in vitro films using high resolution color microscopy. Invest Ophthalmol Vis Sci. 2012;53:4710–4719
17. Herok GH, Mudgil P, Millar TJ. The effect of meibomian lipids and tear proteins on evaporation rate under controlled in vitro conditions. Curr Eye Res. 2009;34:589–597
18. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716–726
19. Ammar D, Noecker R, Kahook M. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27:837–845
20. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: The good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–334
21. Bangham AD, Standish, MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13:238–252
22. Millar TJ, Tragoulias ST, Anderton PJ, et al. The surface activity of purified ocular mucin at the air-liquid interface and interactions with meibomian lipids. Cornea. 2006;25:91–100
23. Yasueda SIK, Matsuhisa K, Terayama H, Ohtori A. Evaluation of ophthalmic suspensions using surface tension. Eur J Pharm Biopharm. 2004;57:377–382
24. Purslow C, Wolffsohn JS. Ocular surface temperature: a review. Eye Contact Lens. 2005;31:117–123
25. Budai L, Hajdu M, Budai M, et al. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm. 2007;343:34–40
26. Sechoy O, Tissie G, Sebastian C, Maurin F, Driot JY, Trinquand C. A new long acting ophthalmic formulation of carteolol containing alginic acid. Int J Pharm. 2000;207:109–116
27. Diebold Y, Calonge M, Enríquez de Salamanca A, et al. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Invest Ophthalmol Visl Sci. 2003;44:4263–4274
28. Girón N, Través P, Rodríguez B, et al. Supression of inflammatory responses by labdane-type diterpenoids. Toxicol Appl Pharmacol. 2008;228:179–189
29. Andres-Guerrero V, Vicario-de-la-Torre M, Molina-Martinez IT, Benitez-del-Castillo JM, Garcia-Feijoo J, Herrero-Vanrell R. Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers. Invest Ophthalmol Vis Sci. 2011; 52:3548–3556
30. Scudiero DA, Shoemaker RH, Paul KP, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;4827–4833
31. Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem. 1997;69:581–593
32. Saarinen-Savolainen P, Järvinen T, Araki-Sasaki K, Watanabe H, Urtti A. Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line. Pharm Res. 1998;15:1275–1280
33. Pellinen P, Huhtala A, Tolonen A, Lokkila J, Maenpaa J, Uusitalo H. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. Curr Eye Res. 2012;37:145–154
34. Seibold LK, Ammar DA, Kahook MY. Acute effects of glaucoma medications and benzalkonium chloride on pre-adipocyte proliferation and adipocyte cytotoxicity in vitro. Curr Eye Res. 2012;38:70–74
35. Enríquez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci. 2006;47:1416–1425
36. Takeuchi H, Yamamoto H, Toyoda T, Toyobuku H, Hino T, Kawashima Y. Physical stability of size controlled small unilameller liposomes coated with a modified polyvinyl alcohol. Int J Pharm. 1998;164:103–111
37. Lasic DD. Novel applications of liposomes. Trends Biotechnol. 1998;16:307–321
38. Yamaguchi M, Ueda K, Isowaki A, et al. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. Biol Pharm Bull. 2009;32:1266–1271
39. Tiffany JM. The viscosity of human tears. Int Ophthalmol. 1991;15:371–376
40. Lemp MA, Baudouin C, Baum J, et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf.2007;5:75–92
41. Sweeney DF, Millar TJ, Raju SR. Tear film stability: a review. Exp Eye Res. 2013;117:28–38
42. Gipson IK. Age-related changes and diseases of the ocular surface and cornea. Invest Ophthalmol Vis Sci. 2013;54: ORSF48–53
43. Calonge M. The treatment of dry eye. Surv Ophthalmol. 2001; 45:S227–S239
44. Lee SY, Tong L. Lipid-containing lubricants for dry eye: a systematic review. Optom Vis Sci. 2012;89:1654–1661
45. Hecht G. Ophthalmic preparations. In: University of Sciences in Philadelphia, ed. Remington: The Science and Practice of Pharmacy. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001:821–833
46. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4:297–305
47. Berger N, Sachse A, Bender J, Schubert R, Brandl M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm. 2001;31:55–68
48. Baeyens V, Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv. 1997;72:191–202
49. Carney LG, Mauger TF, Hill RM. Buffering in human tears: pH responses to acid and base challenge. Invest Ophthalmol Vis Sci. 1989;30:747–754
50. Yamada M, Kawai M, Mochizuki H, Hata Y, Mashima Y. Fluorophotometric measurement of the buffering action of human tears in vivo. Curr Eye Res. 1998;17:1005–1009
51. Holly FJ, Lemp MA. Wettability and wetting of corneal epithelium. Exp Eye Res. 1971;11:239–250
52. Tiffany JM. Tears in health and disease. Eye. 2003;17:923–926
53. Bron AJ, Tiffany JM, Gouveia SM, Yokoi N, Voon LW. Functional aspects of the tear film lipid layer. Exp Eye Res. 2004;78:347–360
54. Glasgow BJ, Marshall G, Gasymov OK, Abduragimov AR, Yusifov TN, Knobler CM. Tear lipocalins: potential lipid scavengers for the corneal surface. Invest Ophthalmol Vis Sci. 1999;40:3100–3107
55. Mantelli F, Massaro-Giordano M, Macchi I, Lambiase A, Bonini S. The cellular mechanisms of dry eye: from pathogenesis to treatment. J Cell Physiol. 2013;228:2253–2256
56. Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci. 2006;47:4309–4315
57. Gary NF. The correlation between the tear film lipid layer and dry eye disease. Surv Ophthalmol. 2007;52:369–374
58. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57:1595–1639
59. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269:1–14
60. Prieto JG, Pulido MM, Zapico J, et al. Comparative study of hyaluronic derivatives: rheological behaviour, mechanical and chemical degradation. Int J Biol Macromol. 2005;35:63–69
61. Falcone SJ, Palmeri DM, Berg RA. Rheological and cohesive properties of hyaluronic acid. J Biomed Mater Res A. 2006; 76A:721–728
62. Chong BF, Blank LM, McLaughlin R, Nielsen LK. Microbial hyaluronic acid production. Appl Microbiol Biotechnol. 2005; 66:341–351
63. Akram M, Shyum S, Gauhar S. Development of new ophthalmic suspension prednisolone acetate 1%. Pak J Pharm Sci. 2010;23:149–154
64. Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Inter J Pharm. 2010;396:179–187
65. Bravo-Osuna I, Noiray M, Briand E, et al. Interfacial interaction between transmembrane ocular mucins and adhesive polymers and dendrimers analyzed by surface plasmon resonance. Pharm Res. 2012;29:2329–2340
66. Nakamura S, Okada S, Umeda Y, Saito F. Development of a rabbit model of tear film instability and evaluation of viscosity of artificial tear preparations. Cornea. 2004;23:390–397
67. Park Y, Cho S, Linhardt RJ. Exploration of the action pattern of Streptomyces hyaluronate lyase using high-resolution capillary electrophoresis. Biochim Biophys Acta. 1997;1337:217–226
68. Jedrzejas, JM, Mello LV, de Groot BL, Li S. Mechanism of hyaluronan degradation by streptococcus pneumoniae hyaluronate lyase. J Biol Chem. 2002;277:28287–28297
69. Freeberg FE, Nixon GA, Reer PJ, et al. Human and rabbit eye responses to chemical insult. Fundam Appl Toxicol. 1986;7: 626–634
70. Walker AP. A more realistic animal technique for predicting human eye response. Food Chem Toxicol. 1985;23:175–178
71. Lambert LA, Chambers WA, Green S, et al. The use of lowvolume dosing in the eye irritation test. Food Chem Toxicol. 1993;31:99–103.